Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 371–380 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 371
- Medicine slug
- darifenacin
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 10
- Source count
- 10
- Agreement rate
- 1
- Recorded readings
163 L
- Numeric value
- 163
- Unit
- L
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)
Darifenacin label
Version not recorded · Effective date not recorded
The steady-state volume of distribution (V ss ) is estimated to be 163 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62a72d3e-3c33-4f2d-b3d0-2e014f704c63 (opens source in a new tab)
Darifenacin label
Version not recorded · Effective date not recorded
The steady-state volume of distribution (V ss ) is estimated to be 163 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ac2cb5a-c0bb-40e2-95d5-1b91a13036c3 (opens source in a new tab)
Darifenacin label
Version not recorded · Effective date not recorded
The steady-state volume of distribution (Vss) is estimated to be 163 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e84f1ae3-b9a2-4a15-a299-c75373891cc1 (opens source in a new tab)
Darifenacin label
Version not recorded · Effective date not recorded
The steady-state volume of distribution (Vss) is estimated to be 163 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2aa9544-0136-463d-a73b-1a299534446a (opens source in a new tab)
Darifenacin label
Version not recorded · Effective date not recorded
The steady-state volume of distribution (V ss ) is estimated to be 163 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:697eba55-9e1f-4036-baed-5644c810f166 (opens source in a new tab)
Darifenacin label
Version not recorded · Effective date not recorded
The steady-state volume of distribution (Vss) is estimated to be 163 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:28ed5b58-46dd-4140-a877-4b422f780a94 (opens source in a new tab)
Darifenacin label
Version not recorded · Effective date not recorded
The steady-state volume of distribution (V ss ) is estimated to be 163 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ae60119-e22c-4806-a5d8-db7c9e8984a2 (opens source in a new tab)
Darifenacin label
Version not recorded · Effective date not recorded
The steady-state volume of distribution (Vss) is estimated to be 163 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da7c2732-232c-4e71-92d9-577ef8617f56 (opens source in a new tab)
Darifenacin label
Version not recorded · Effective date not recorded
The steady-state volume of distribution (Vss) is estimated to be 163 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f6952c8-e547-4f3e-a978-a88d6ea9dc10 (opens source in a new tab)
Darifenacin label
Version not recorded · Effective date not recorded
The steady-state volume of distribution (Vss) is estimated to be 163 L.
Projected row 372
- Medicine slug
- darunavir
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 14
- Source count
- 14
- Agreement rate
- 1
- Recorded readings
15 hours
- Numeric value
- 15
- Unit
- hours
- Source records
- 14
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 14 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88910ad0-6dc3-4a47-8a6b-5c6ee79f2a93 (opens source in a new tab)
Darunavir label
Version not recorded · Effective date not recorded
The terminal elimination half-life of darunavir was approximately 15 hours when co-administered with ritonavir.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5624cc30-d484-458e-b234-9bb745a118ca (opens source in a new tab)
Darunavir label
Version not recorded · Effective date not recorded
The terminal elimination half-life of darunavir was approximately 15 hours when co-administered with ritonavir.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:814301f9-c990-46a5-b481-2879a521a16f (opens source in a new tab)
Darunavir label
Version not recorded · Effective date not recorded
The terminal elimination half-life of darunavir was approximately 15 hours when co-administered with ritonavir.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e80e44f8-1987-4b78-a63d-a4e4d5122ddb (opens source in a new tab)
Darunavir label
Version not recorded · Effective date not recorded
The terminal elimination half-life of darunavir was approximately 15 hours when co-administered with ritonavir.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49606d5e-f45f-45eb-9ab8-15aa6a233875 (opens source in a new tab)
Darunavir label
Version not recorded · Effective date not recorded
The terminal elimination half-life of darunavir was approximately 15 hours when co-administered with ritonavir.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56daf67e-7501-4cd5-be22-566d7997d42e (opens source in a new tab)
Darunavir label
Version not recorded · Effective date not recorded
The terminal elimination half-life of darunavir was approximately 15 hours when co-administered with ritonavir.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf99d8b8-c4e0-4cb4-924e-8cdcfd8d1aa1 (opens source in a new tab)
Darunavir label
Version not recorded · Effective date not recorded
The terminal elimination half-life of darunavir was approximately 15 hours when co-administered with ritonavir.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42cc1b58-2660-f0be-e063-6394a90abe4c (opens source in a new tab)
Darunavir label
Version not recorded · Effective date not recorded
The terminal elimination half-life of darunavir was approximately 15 hours when co-administered with ritonavir.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:632293b0-d220-444e-8a5b-2ee8c225b66d (opens source in a new tab)
Darunavir label
Version not recorded · Effective date not recorded
The terminal elimination half-life of darunavir was approximately 15 hours when co-administered with ritonavir.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ea6e0136-75b2-4793-9500-04e6658a0a73 (opens source in a new tab)
Darunavir label
Version not recorded · Effective date not recorded
The terminal elimination half-life of darunavir was approximately 15 hours when co-administered with ritonavir.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04a542b3-15ad-4a8a-aab4-ace8e08732f3 (opens source in a new tab)
Darunavir label
Version not recorded · Effective date not recorded
The terminal elimination half-life of darunavir was approximately 15 hours when co-administered with ritonavir.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:64160982-e682-4e8d-8800-a89321112211 (opens source in a new tab)
Darunavir label
Version not recorded · Effective date not recorded
The terminal elimination half-life of darunavir was approximately 15 hours when co-administered with ritonavir.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92b286d5-1ee5-435b-9e1d-2e95c7f2ec69 (opens source in a new tab)
Darunavir label
Version not recorded · Effective date not recorded
The terminal elimination half-life of darunavir was approximately 15 hours when co-administered with ritonavir.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5c9cb01-6530-4db0-a326-22a499d1efdf (opens source in a new tab)
Darunavir label
Version not recorded · Effective date not recorded
The terminal elimination half-life of darunavir was approximately 15 hours when co-administered with ritonavir.
Projected row 373
- Medicine slug
- darunavir
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 14
- Source count
- 14
- Agreement rate
- 0.928571
- Recorded readings
2.5 to 4 hours
- Numeric value
- 2.5
- Unit
- hours
- Source records
- 13
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 13 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88910ad0-6dc3-4a47-8a6b-5c6ee79f2a93 (opens source in a new tab)
Darunavir label
Version not recorded · Effective date not recorded
Absorption and Bioavailability Darunavir, co-administered with 100 mg ritonavir twice daily, was absorbed following oral administration with a T max of approximately 2.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5624cc30-d484-458e-b234-9bb745a118ca (opens source in a new tab)
Darunavir label
Version not recorded · Effective date not recorded
Absorption and Bioavailability Darunavir, co-administered with 100 mg ritonavir twice daily, was absorbed following oral administration with a T max of approximately 2.5-4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:814301f9-c990-46a5-b481-2879a521a16f (opens source in a new tab)
Darunavir label
Version not recorded · Effective date not recorded
3198) 3197 (250–11865) 3539 (1255–7368) Absorption and Bioavailability Darunavir, co-administered with 100 mg ritonavir twice daily, was absorbed following oral administration with a T max of approximately 2.5–4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e80e44f8-1987-4b78-a63d-a4e4d5122ddb (opens source in a new tab)
Darunavir label
Version not recorded · Effective date not recorded
Absorption and Bioavailability Darunavir, co-administered with 100 mg ritonavir twice daily, was absorbed following oral administration with a T max of approximately 2.5-4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49606d5e-f45f-45eb-9ab8-15aa6a233875 (opens source in a new tab)
Darunavir label
Version not recorded · Effective date not recorded
Absorption and Bioavailability Darunavir, co-administered with 100 mg ritonavir twice daily, was absorbed following oral administration with a T max of approximately 2.5-4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56daf67e-7501-4cd5-be22-566d7997d42e (opens source in a new tab)
Darunavir label
Version not recorded · Effective date not recorded
97 (250 to 11865) 3539 (1255 to 7368) Absorption and Bioavailability Darunavir, co-administered with 100 mg ritonavir twice daily, was absorbed following oral administration with a T max of approximately 2.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf99d8b8-c4e0-4cb4-924e-8cdcfd8d1aa1 (opens source in a new tab)
Darunavir label
Version not recorded · Effective date not recorded
Absorption and Bioavailability Darunavir, co-administered with 100 mg ritonavir twice daily, was absorbed following oral administration with a T max of approximately 2.5-4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42cc1b58-2660-f0be-e063-6394a90abe4c (opens source in a new tab)
Darunavir label
Version not recorded · Effective date not recorded
Absorption and Bioavailability Darunavir, co-administered with 100 mg ritonavir twice daily, was absorbed following oral administration with a T max of approximately 2.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:632293b0-d220-444e-8a5b-2ee8c225b66d (opens source in a new tab)
Darunavir label
Version not recorded · Effective date not recorded
55-7368) N=number of subjects with data Absorption and Bioavailability Darunavir, co-administered with 100 mg ritonavir twice daily, was absorbed following oral administration with a T max of approximately 2.5-4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ea6e0136-75b2-4793-9500-04e6658a0a73 (opens source in a new tab)
Darunavir label
Version not recorded · Effective date not recorded
Absorption and Bioavailability Darunavir, co-administered with 100 mg ritonavir twice daily, was absorbed following oral administration with a T max of approximately 2.5-4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:64160982-e682-4e8d-8800-a89321112211 (opens source in a new tab)
Darunavir label
Version not recorded · Effective date not recorded
Absorption and Bioavailability Darunavir, co-administered with 100 mg ritonavir twice daily, was absorbed following oral administration with a T max of approximately 2.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92b286d5-1ee5-435b-9e1d-2e95c7f2ec69 (opens source in a new tab)
Darunavir label
Version not recorded · Effective date not recorded
Absorption and Bioavailability Darunavir, co-administered with 100 mg ritonavir twice daily, was absorbed following oral administration with a T max of approximately 2.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5c9cb01-6530-4db0-a326-22a499d1efdf (opens source in a new tab)
Darunavir label
Version not recorded · Effective date not recorded
Absorption and Bioavailability Darunavir, co-administered with 100 mg ritonavir twice daily, was absorbed following oral administration with a T max of approximately 2.5 to 4 hours.
2.5 hours
- Numeric value
- 2.5
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04a542b3-15ad-4a8a-aab4-ace8e08732f3 (opens source in a new tab)
Darunavir label
Version not recorded · Effective date not recorded
7 (250 to 11,865) 3,539 (1,255 to 7,368) Absorption and Bioavailability Darunavir, co-administered with 100 mg ritonavir twice daily, was absorbed following oral administration with a T max of approximately 2.5 hours to 4 hours.
Projected row 374
- Medicine slug
- dasatinib
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 15
- Source count
- 15
- Agreement rate
- 0.933333
- Recorded readings
3 hours
- Numeric value
- 3
- Unit
- hours
- Source records
- 14
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 14 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eb5ddff2-6521-b461-43ac-80ff8660b20b (opens source in a new tab)
Dasatinib label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life of dasatinib is 3 hours to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11703145-29ea-480a-9810-bc70663b783f (opens source in a new tab)
Dasatinib label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life of dasatinib is 3 hours to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3000fd91-1b09-4d72-8522-1ca5e35ed956 (opens source in a new tab)
Dasatinib label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life of dasatinib is 3 hours to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de3215a4-d098-4bc3-ad81-c7c9e3493872 (opens source in a new tab)
Dasatinib label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life of dasatinib is 3 hours to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:645fcf26-1b2f-40c5-881b-8effe02defbd (opens source in a new tab)
Dasatinib label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life of dasatinib is 3 hours to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43e078b9-4e0b-edeb-e063-6294a90a7586 (opens source in a new tab)
Dasatinib label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life of dasatinib is 3 hours to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f60261dd-b8ea-4511-bed6-ad6d7f4dd828 (opens source in a new tab)
Dasatinib label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life of dasatinib is 3 hours to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ed87763-f018-abdb-c0ab-daa5e441b397 (opens source in a new tab)
Dasatinib label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life of dasatinib is 3 hours to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4764f37b-c9e6-4ede-bcc2-8a03b7c521df (opens source in a new tab)
Dasatinib label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life of dasatinib is 3 hours to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9b79d54-9bee-4c93-9c87-f3e65d91f146 (opens source in a new tab)
Dasatinib label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life of dasatinib is 3 hours to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:76e1833c-e105-5a3d-0f01-1330d8cc7ae1 (opens source in a new tab)
Dasatinib label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life of dasatinib is 3 hours to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4 (opens source in a new tab)
Dasatinib label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life of dasatinib is 3 hours to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58ce42c6-10bd-4bb4-bf89-eae8ed82c339 (opens source in a new tab)
Dasatinib label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life of dasatinib is 3 hours to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1931e73f-918c-4d69-9543-de9643513d05 (opens source in a new tab)
Dasatinib label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life of dasatinib is 3 hours to 5 hours.
5 hours
- Numeric value
- 5
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:60976d1e-c415-417f-8168-4e07999a7281 (opens source in a new tab)
Dasatinib label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life of PHYRAGO is 5 hours and the geometric mean (%CV) apparent clearance is 241 L/hr (54.4%).
Projected row 375
- Medicine slug
- dasatinib
- Compared field
- volumeOfDistribution
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 15
- Source count
- 15
- Agreement rate
- 0.733333
- Recorded readings
2505 L
- Numeric value
- 2,505
- Unit
- L
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eb5ddff2-6521-b461-43ac-80ff8660b20b (opens source in a new tab)
Dasatinib label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution is 2505 L (CV% 93%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3000fd91-1b09-4d72-8522-1ca5e35ed956 (opens source in a new tab)
Dasatinib label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution is 2505 L (CV% 93%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de3215a4-d098-4bc3-ad81-c7c9e3493872 (opens source in a new tab)
Dasatinib label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution is 2505 L (CV% 93%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:645fcf26-1b2f-40c5-881b-8effe02defbd (opens source in a new tab)
Dasatinib label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution is 2505 L (CV% 93%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43e078b9-4e0b-edeb-e063-6294a90a7586 (opens source in a new tab)
Dasatinib label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution is 2505 L (CV% 93%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f60261dd-b8ea-4511-bed6-ad6d7f4dd828 (opens source in a new tab)
Dasatinib label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution is 2505 L (CV% 93%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4764f37b-c9e6-4ede-bcc2-8a03b7c521df (opens source in a new tab)
Dasatinib label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution is 2505 L (CV% 93%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9b79d54-9bee-4c93-9c87-f3e65d91f146 (opens source in a new tab)
Dasatinib label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution is 2505 L (CV% 93%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:76e1833c-e105-5a3d-0f01-1330d8cc7ae1 (opens source in a new tab)
Dasatinib label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution is 2505 L (CV% 93%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4 (opens source in a new tab)
Dasatinib label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution is 2505 L (CV% 93%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1931e73f-918c-4d69-9543-de9643513d05 (opens source in a new tab)
Dasatinib label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution is 2505 L (CV% 93%).
2,505 L
- Numeric value
- 2,505
- Unit
- L
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11703145-29ea-480a-9810-bc70663b783f (opens source in a new tab)
Dasatinib label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution is 2,505 L (CV% 93%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ed87763-f018-abdb-c0ab-daa5e441b397 (opens source in a new tab)
Dasatinib label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution is 2,505 L (CV% 93%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58ce42c6-10bd-4bb4-bf89-eae8ed82c339 (opens source in a new tab)
Dasatinib label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution is 2,505 L (CV% 93%).
1850 L
- Numeric value
- 1,850
- Unit
- L
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:60976d1e-c415-417f-8168-4e07999a7281 (opens source in a new tab)
Dasatinib label
Version not recorded · Effective date not recorded
Distribution The geometric mean (%CV) apparent volume of distribution for PHYRAGO is 1850 L (59.3%).
Projected row 376
- Medicine slug
- daunorubicin
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 4
- Source count
- 4
- Agreement rate
- 1
- Recorded readings
18.5 hours
- Numeric value
- 18.5
- Unit
- hours
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:227784a8-ce68-4dd4-8ac5-a65265969677 (opens source in a new tab)
Daunorubicin label
Version not recorded · Effective date not recorded
Thereafter, plasma levels decline slowly with a half-life of 45 minutes in the initial phase and 18.5 hours in the terminal phase.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4312095-3c21-296b-e053-2995a90a0d9c (opens source in a new tab)
Daunorubicin label
Version not recorded · Effective date not recorded
Thereafter, plasma levels decline slowly with a half-life of 45 minutes in the initial phase and 18.5 hours in the terminal phase.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9705fa12-499e-41a3-8fb4-f6df0858b851 (opens source in a new tab)
Daunorubicin label
Version not recorded · Effective date not recorded
Thereafter, plasma levels decline slowly with a half-life of 45 minutes in the initial phase and 18.5 hours in the terminal phase.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff6b9bd4-8a9f-400f-a0b9-70e25fa8a28f (opens source in a new tab)
Daunorubicin label
Version not recorded · Effective date not recorded
Thereafter, plasma levels decline slowly with a half-life of 45 minutes in the initial phase and 18.5 hours in the terminal phase.
Projected row 377
- Medicine slug
- deferasirox
- Compared field
- bioavailability
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 31
- Source count
- 31
- Agreement rate
- 0.419355
- Recorded readings
36%
- Numeric value
- 36
- Unit
- %
- Source records
- 13
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 13 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:485c4834-7bec-2018-e063-6294a90ab4e3 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The bioavailability (as measured by AUC inf ) of deferasirox tablets was 36% greater than with deferasirox tablets for oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1f952c8-89f5-4a2f-bd6b-9b384366d971 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The bioavailability (as measured by AUC inf ) of deferasirox tablets was 36% greater than with deferasirox tablets for oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57cf1650-88f9-474e-9e19-df451a15619d (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The bioavailability (as measured by AUC inf ) of deferasirox tablets was 36% greater than with deferasirox tablets for oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fee89140-fff1-4443-9f42-24ac004fcda1 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The bioavailability (as measured by AUC inf ) of JADENU tablets was 36% greater than with deferasirox tablets for oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0fb210b3-6a3d-4313-83ce-52012e384f9b (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The bioavailability (as measured by AUC inf ) of deferasirox tablets was 36% greater than with deferasirox tablets for oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4af5bc9e-3e09-4dfd-8cc8-7677953c9c7c (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The bioavailability (as measured by AUC inf ) of deferasirox tablets was 36% greater than with deferasirox tablets for oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7ae9c31-e14f-4cf9-9ab3-850519f1a87c (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The bioavailability (as measured by AUC inf ) of deferasirox tablets was 36% greater than with deferasirox tablets for oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c36bb5a-2552-46c1-8500-4ae783cffef1 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The bioavailability (as measured by AUC inf ) of deferasirox tablets was 36% greater than with deferasirox tablets for oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0354cbc7-9b32-4513-976a-2ef2da39b6b3 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The bioavailability (as measured by AUC inf ) of deferasirox tablets was 36% greater than with deferasirox tablets for oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:350dfc39-d03d-e221-22e9-3880728c955c (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The bioavailability (as measured by AUC inf ) of deferasirox tablets was 36% greater than with deferasirox tablets for oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd9450f4-7c95-4322-8806-9820570f5aa2 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The bioavailability (as measured by AUC inf ) of deferasirox tablets was 36% greater than with deferasirox tablets for oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65453013-c360-4835-8358-2a278a4a32db (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The bioavailability (as measured by AUC inf ) of deferasirox tablets was 36% greater than with deferasirox tablets for oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7f14819-1abc-4abf-b55b-cf89beaf124e (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The bioavailability (as measured by AUC inf ) of deferasirox tablets was 36% greater than with deferasirox tablets for oral suspension.
70%
- Numeric value
- 70
- Unit
- %
- Source records
- 12
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 12 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e365e748-4b61-94f2-fb7a-f81919eaccaa (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The absolute bioavailability (AUC) of deferasirox tablets for oral suspension is 70% compared to an intravenous dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3495a70c-870c-4968-940e-8baea152cf85 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The absolute bioavailability (AUC) of deferasirox tablets for oral suspension is 70% compared to an intravenous dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0726c9c-cee8-4fc1-abd1-68ad0db030dd (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The absolute bioavailability (AUC) of deferasirox tablets for oral suspension is 70% compared to an intravenous dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a03c7657-fdca-4acb-ad82-c24680e90eae (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The absolute bioavailability (AUC) of deferasirox tablets for oral suspension is 70% compared to an intravenous dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f9f1a69-bf71-4e6a-88b0-90f08c4da79f (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The absolute bioavailability (AUC) of deferasirox tablets for oral suspension is 70% compared to an intravenous dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc690f20-533e-490e-b13d-143382e02351 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The absolute bioavailability (AUC) of deferasirox tablets for oral suspension is 70% compared to an intravenous dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da3295fc-5210-46a3-a5cc-7b9ec9265eca (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The absolute bioavailability (AUC) of deferasirox tablets for oral suspension is 70% compared to an intravenous dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59f1d3fb-5bdb-4261-8557-9a4bde8b3c1c (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The absolute bioavailability (AUC) of deferasirox tablets for oral suspension is 70% compared to an intravenous dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9054806-2721-4736-9aef-81ffb8db75d1 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The absolute bioavailability (AUC) of deferasirox tablets for oral suspension is 70% compared to an intravenous dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c8b84f3-6887-4485-b5e0-03f254b88a15 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The absolute bioavailability (AUC) of deferasirox tablets for oral suspension is 70% compared to an intravenous dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad73cb1f-41d6-4cde-9abc-fc2cb7e04c95 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The absolute bioavailability (AUC) of deferasirox tablets for oral suspension is 70% compared to an intravenous dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a2e1bd2-9f3a-40ec-94a2-bc76350d6d4b (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The absolute bioavailability (AUC) of deferasirox tablets for oral suspension is 70% compared to an intravenous dose.
52%
- Numeric value
- 52
- Unit
- %
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eded6687-ba78-4117-a316-eec56d46a08a (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
Granules The bioavailability (as measured by AUC inf ) of deferasirox oral granules was 52% greater than with deferasirox tablets for oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7eda83c3-a282-47f6-9f06-d2f9612f5c5b (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
Granules The bioavailability (as measured by AUC inf ) of deferasirox oral granules was 52% greater than with deferasirox tablets for oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c220484e-1e6a-4a0c-a221-60223f3bc24c (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
Granules The bioavailability (as measured by AUC inf ) of deferasirox oral granules was 52% greater than with deferasirox tablets for oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1122f1c0-c160-49db-a31b-90d7521370f5 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
Granules The bioavailability (as measured by AUC inf ) of deferasirox oral granules was 52% greater than with deferasirox tablets for oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c2842a0-7781-4047-84cd-88bd018e10c7 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
Granules The bioavailability (as measured by AUC inf ) of deferasirox oral granules was 52% greater than with deferasirox tablets for oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:31c5a91f-e901-418b-a519-779a0c245477 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
Granules The bioavailability (as measured by AUC inf ) of deferasirox granules was 52% greater than with deferasirox tablets for oral suspension.
Projected row 378
- Medicine slug
- deferasirox
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 31
- Source count
- 31
- Agreement rate
- 0.967742
- Recorded readings
8 to 16 hours
- Numeric value
- 8
- Unit
- hours
- Source records
- 30
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 30 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e365e748-4b61-94f2-fb7a-f81919eaccaa (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8 to 16 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:485c4834-7bec-2018-e063-6294a90ab4e3 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8 to 16 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1f952c8-89f5-4a2f-bd6b-9b384366d971 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8 to 16 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eded6687-ba78-4117-a316-eec56d46a08a (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8 to 16 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3495a70c-870c-4968-940e-8baea152cf85 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8-16 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0726c9c-cee8-4fc1-abd1-68ad0db030dd (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8 to 16 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7eda83c3-a282-47f6-9f06-d2f9612f5c5b (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8 to 16 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a03c7657-fdca-4acb-ad82-c24680e90eae (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8 to 16 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57cf1650-88f9-474e-9e19-df451a15619d (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8 to 16 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fee89140-fff1-4443-9f42-24ac004fcda1 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8 to 16 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0fb210b3-6a3d-4313-83ce-52012e384f9b (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8 to 16 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f9f1a69-bf71-4e6a-88b0-90f08c4da79f (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8 to 16 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da3295fc-5210-46a3-a5cc-7b9ec9265eca (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8 to 16 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59f1d3fb-5bdb-4261-8557-9a4bde8b3c1c (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8 to 16 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4af5bc9e-3e09-4dfd-8cc8-7677953c9c7c (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8 to 16 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7ae9c31-e14f-4cf9-9ab3-850519f1a87c (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8 to 16 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c220484e-1e6a-4a0c-a221-60223f3bc24c (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8 to 16 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c36bb5a-2552-46c1-8500-4ae783cffef1 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8 to 16 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0354cbc7-9b32-4513-976a-2ef2da39b6b3 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8 to 16 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:350dfc39-d03d-e221-22e9-3880728c955c (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8 to 16 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd9450f4-7c95-4322-8806-9820570f5aa2 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8 to 16 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1122f1c0-c160-49db-a31b-90d7521370f5 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8 to 16 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c2842a0-7781-4047-84cd-88bd018e10c7 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8 to 16 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9054806-2721-4736-9aef-81ffb8db75d1 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8-16 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65453013-c360-4835-8358-2a278a4a32db (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8 to 16 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c8b84f3-6887-4485-b5e0-03f254b88a15 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8 to 16 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:31c5a91f-e901-418b-a519-779a0c245477 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8 to 16 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad73cb1f-41d6-4cde-9abc-fc2cb7e04c95 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8 to 16 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a2e1bd2-9f3a-40ec-94a2-bc76350d6d4b (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8 to 16 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7f14819-1abc-4abf-b55b-cf89beaf124e (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8 to 16 hours following oral administration.
8 hours
- Numeric value
- 8
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc690f20-533e-490e-b13d-143382e02351 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The mean elimination half-life (t 1/2 ) ranged from 8 hours to 16 hours following oral administration.
Projected row 379
- Medicine slug
- deferasirox
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 31
- Source count
- 31
- Agreement rate
- 0.967742
- Recorded readings
1.5 to 4 hours
- Numeric value
- 1.5
- Unit
- hours
- Source records
- 30
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 30 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e365e748-4b61-94f2-fb7a-f81919eaccaa (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Deferasirox is absorbed following oral administration with median times to maximum plasma concentration (T max ) of about 1.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:485c4834-7bec-2018-e063-6294a90ab4e3 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Based on studies in patients with the tablet for oral suspension, deferasirox is absorbed following oral administration with median times to maximum plasma concentration (T max ) of about 1.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1f952c8-89f5-4a2f-bd6b-9b384366d971 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Based on studies in patients with the tablet for oral suspension, deferasirox is absorbed following oral administration with median times to maximum plasma concentration (T max ) of about 1.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eded6687-ba78-4117-a316-eec56d46a08a (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Based on studies in patients with the tablet for oral suspension, deferasirox is absorbed following oral administration with median times to maximum plasma concentration (T max ) of about 1.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3495a70c-870c-4968-940e-8baea152cf85 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Exjade is absorbed following oral administration with median times to maximum plasma concentration (T max ) of about 1.5-4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0726c9c-cee8-4fc1-abd1-68ad0db030dd (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Deferasirox is absorbed following oral administration with median times to maximum plasma concentration (T max ) of about 1.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7eda83c3-a282-47f6-9f06-d2f9612f5c5b (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Based on studies in patients with the tablet for oral suspension, deferasirox is absorbed following oral administration with median times to maximum plasma concentration (T max ) of about 1.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a03c7657-fdca-4acb-ad82-c24680e90eae (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Deferasirox is absorbed following oral administration with median times to maximum plasma concentration (T max ) of about 1.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57cf1650-88f9-474e-9e19-df451a15619d (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Based on studies in patients with the tablet for oral suspension, deferasirox is absorbed following oral administration with median times to maximum plasma concentration (T max ) of about 1.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fee89140-fff1-4443-9f42-24ac004fcda1 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Based on studies in patients with the tablet for oral suspension, deferasirox is absorbed following oral administration with median times to maximum plasma concentration (T max ) of about 1.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0fb210b3-6a3d-4313-83ce-52012e384f9b (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Based on studies in patients with the tablet for oral suspension, deferasirox is absorbed following oral administration with median times to maximum plasma concentration (T max ) of about 1.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f9f1a69-bf71-4e6a-88b0-90f08c4da79f (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Deferasirox tablets for oral suspension are absorbed following oral administration with median times to maximum plasma concentration (T max ) of about 1.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da3295fc-5210-46a3-a5cc-7b9ec9265eca (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Deferasirox is absorbed following oral administration with median times to maximum plasma concentration (T max ) of about 1.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59f1d3fb-5bdb-4261-8557-9a4bde8b3c1c (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Deferasirox is absorbed following oral administration with median times to maximum plasma concentration (T max ) of about 1.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4af5bc9e-3e09-4dfd-8cc8-7677953c9c7c (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Based on studies in patients with the tablet for oral suspension, deferasirox is absorbed following oral administration with median times to maximum plasma concentration (T max ) of about 1.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7ae9c31-e14f-4cf9-9ab3-850519f1a87c (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Based on studies in patients with the tablet for oral suspension, deferasirox is absorbed following oral administration with median times to maximum plasma concentration (T max ) of about 1.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c220484e-1e6a-4a0c-a221-60223f3bc24c (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Based on studies in patients with the tablet for oral suspension, deferasirox is absorbed following oral administration with median times to maximum plasma concentration (T max ) of about 1.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c36bb5a-2552-46c1-8500-4ae783cffef1 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Based on studies in patients with the tablet for oral suspension, deferasirox is absorbed following oral administration with median times to maximum plasma concentration (T max ) of about 1.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0354cbc7-9b32-4513-976a-2ef2da39b6b3 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Based on studies in patients with the tablet for oral suspension, deferasirox is absorbed following oral administration with median times to maximum plasma concentration (T max ) of about 1.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:350dfc39-d03d-e221-22e9-3880728c955c (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Based on studies in patients with the tablet for oral suspension, deferasirox is absorbed following oral administration with median times to maximum plasma concentration (T max ) of about 1.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd9450f4-7c95-4322-8806-9820570f5aa2 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Based on studies in patients with the tablet for oral suspension, deferasirox is absorbed following oral administration with median times to maximum plasma concentration (T max ) of about 1.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1122f1c0-c160-49db-a31b-90d7521370f5 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Based on studies in patients with the tablet for oral suspension, deferasirox is absorbed following oral administration with median times to maximum plasma concentration (T max ) of about 1.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c2842a0-7781-4047-84cd-88bd018e10c7 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Based on studies in patients with the tablet for oral suspension, deferasirox is absorbed following oral administration with median times to maximum plasma concentration (T max ) of about 1.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9054806-2721-4736-9aef-81ffb8db75d1 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Deferasirox is absorbed following oral administration with median times to maximum plasma concentration (Tmax) of about 1.5-4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65453013-c360-4835-8358-2a278a4a32db (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Based on studies in patients with the tablet for oral suspension, deferasirox is absorbed following oral administration with median times to maximum plasma concentration (T max ) of about 1.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c8b84f3-6887-4485-b5e0-03f254b88a15 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Deferasirox tablets for oral suspension are absorbed following oral administration with median times to maximum plasma concentration (T max ) of about 1.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:31c5a91f-e901-418b-a519-779a0c245477 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Based on studies in patients with the tablet for oral suspension, deferasirox is absorbed following oral administration with median times to maximum plasma concentration (T max ) of about 1.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad73cb1f-41d6-4cde-9abc-fc2cb7e04c95 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
Cardiac Electrophysiology At the maximum approved recommended dose, deferasirox does not prolong the QT interval to any clinically relevant extent. 12.3 Pharmacokinetics Absorption Deferasirox is absorbed following oral administration with median times to maximum plasma concentration (T max ) of about 1.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a2e1bd2-9f3a-40ec-94a2-bc76350d6d4b (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Deferasirox is absorbed following oral administration with median times to maximum plasma concentration (T max ) of about 1.5 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7f14819-1abc-4abf-b55b-cf89beaf124e (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Based on studies in patients with the tablet for oral suspension, deferasirox is absorbed following oral administration with median times to maximum plasma concentration (T max ) of about 1.5 to 4 hours.
1.5 hours
- Numeric value
- 1.5
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc690f20-533e-490e-b13d-143382e02351 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Deferasirox is absorbed following oral administration with median times to maximum plasma concentration (T max ) of about 1.5 hours to 4 hours.
Projected row 380
- Medicine slug
- deferasirox
- Compared field
- volumeOfDistribution
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 31
- Source count
- 30
- Agreement rate
- 0.966667
- Recorded readings
14.37 ± 2.69 L
- Numeric value
- 14.37
- Unit
- L
- Source records
- 29
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 29 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e365e748-4b61-94f2-fb7a-f81919eaccaa (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The volume of distribution at steady state (V ss ) of deferasirox is 14.37 ± 2.69 L in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:485c4834-7bec-2018-e063-6294a90ab4e3 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The volume of distribution at steady state (V ss ) of deferasirox is 14.37 ± 2.69 L in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1f952c8-89f5-4a2f-bd6b-9b384366d971 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The volume of distribution at steady state (V ss ) of deferasirox is 14.37 ± 2.69 L in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eded6687-ba78-4117-a316-eec56d46a08a (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The volume of distribution at steady state (V ss ) of deferasirox is 14.37 ± 2.69 L in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3495a70c-870c-4968-940e-8baea152cf85 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The volume of distribution at steady state (V ss ) of deferasirox is 14.37 ± 2.69 L in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0726c9c-cee8-4fc1-abd1-68ad0db030dd (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The volume of distribution at steady state (V ss ) of deferasirox is 14.37 ± 2.69 L in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7eda83c3-a282-47f6-9f06-d2f9612f5c5b (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The volume of distribution at steady state (Vss) of deferasirox is 14.37 ± 2.69 L in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a03c7657-fdca-4acb-ad82-c24680e90eae (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The volume of distribution at steady state (V ss ) of deferasirox is 14.37 ± 2.69 L in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57cf1650-88f9-474e-9e19-df451a15619d (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The volume of distribution at steady state (V ss ) of deferasirox is 14.37 ± 2.69 L in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fee89140-fff1-4443-9f42-24ac004fcda1 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The volume of distribution at steady state (V ss ) of deferasirox is 14.37 ± 2.69 L in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0fb210b3-6a3d-4313-83ce-52012e384f9b (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The volume of distribution at steady state (V ss ) of deferasirox is 14.37 ± 2.69 L in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f9f1a69-bf71-4e6a-88b0-90f08c4da79f (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The volume of distribution at steady state (V ss ) of deferasirox is 14.37 ± 2.69 L in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da3295fc-5210-46a3-a5cc-7b9ec9265eca (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The volume of distribution at steady state (V ss ) of deferasirox is 14.37 ± 2.69 L in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59f1d3fb-5bdb-4261-8557-9a4bde8b3c1c (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The volume of distribution at steady state (V ss ) of deferasirox is 14.37 ± 2.69 L in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4af5bc9e-3e09-4dfd-8cc8-7677953c9c7c (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The volume of distribution at steady state (V ss ) of deferasirox is 14.37 ± 2.69 L in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7ae9c31-e14f-4cf9-9ab3-850519f1a87c (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The volume of distribution at steady-state (V ss ) of deferasirox is 14.37 ± 2.69 L in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c220484e-1e6a-4a0c-a221-60223f3bc24c (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The volume of distribution at steady state (V ss ) of deferasirox is 14.37 ± 2.69 L in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c36bb5a-2552-46c1-8500-4ae783cffef1 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The volume of distribution at steady state (Vss) of deferasirox is 14.37 ± 2.69 L in adults Metabolism Glucuronidation is the main metabolic pathway for deferasirox, with subsequent biliary excretion.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0354cbc7-9b32-4513-976a-2ef2da39b6b3 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The volume of distribution at steady state (V ss ) of deferasirox is 14.37 ± 2.69 L in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:350dfc39-d03d-e221-22e9-3880728c955c (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The volume of distribution at steady state (V ss ) of deferasirox is 14.37 ± 2.69 L in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd9450f4-7c95-4322-8806-9820570f5aa2 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The volume of distribution at steady state (V ss ) of deferasirox is 14.37 ± 2.69 L in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c2842a0-7781-4047-84cd-88bd018e10c7 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The volume of distribution at steady state (V ss ) of deferasirox is 14.37 ± 2.69 L in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9054806-2721-4736-9aef-81ffb8db75d1 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The volume of distribution at steady state (V ss ) of deferasirox is 14.37 ± 2.69 L in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65453013-c360-4835-8358-2a278a4a32db (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The volume of distribution at steady state (V ss ) of deferasirox is 14.37 ± 2.69 L in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c8b84f3-6887-4485-b5e0-03f254b88a15 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The volume of distribution at steady state (V ss ) of deferasirox is 14.37 ± 2.69 L in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:31c5a91f-e901-418b-a519-779a0c245477 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The volume of distribution at steady state (V ss ) of deferasirox is 14.37 ± 2.69 L in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad73cb1f-41d6-4cde-9abc-fc2cb7e04c95 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The volume of distribution at steady state (V ss ) of deferasirox is 14.37 ± 2.69 L in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a2e1bd2-9f3a-40ec-94a2-bc76350d6d4b (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The volume of distribution at steady state (V ss ) of deferasirox is 14.37 ± 2.69 L in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7f14819-1abc-4abf-b55b-cf89beaf124e (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The volume of distribution at steady state (V ss ) of deferasirox is 14.37 ± 2.69 L in adults.
14.37 L
- Numeric value
- 14.37
- Unit
- L
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc690f20-533e-490e-b13d-143382e02351 (opens source in a new tab)
Deferasirox label
Version not recorded · Effective date not recorded
The volume of distribution at steady state (V ss ) of deferasirox is 14.37 L ± 2.69 L in adults.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=370Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.